Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Monthly Archives: January 2017

HINJ’s STEM Education Portal Showcases Life Sciences Community’s Investment in Tomorrow’s Innovation Leaders

STEM 1New Brunswick, NJ, January 31, 2016 ― The HealthCare Institute of New Jersey (HINJ) has launched a STEM Education portal that focuses on the life sciences community’s investment in today’s science, technology, engineering and mathematics (STEM) educators and students, who will become tomorrow’s innovation leaders.

HINJ’s new STEM Education portal presents information from a number of sources regarding the current state of STEM education in the United States, its significance to the nation’s and New Jersey’s economic well-being, its importance to advancing medical innovation, and the life sciences industry’ investment in programs designed to advance STEM education. Continue reading

Rutgers Research: New Molecular Discovery May Help Identify Drug Therapies to Treat Dementia

Alzheimer's WordsNew Brunswick, NJ, January 30, 2017 — Robin Lally reports that Rutgers University scientists have discovered a molecular pathway in the brain that may help provide answers to long-term memory problems in the elderly and aid researchers in identifying drug-based therapies to prevent dementia.

“Memory decline brings much suffering to the affected individuals and their families and leads to staggering social and economic costs,” said Gleb Shumyatsky, an associate professor in the Department of Genetics in the School of Arts and Sciences, who co-authored the study with former postdoctoral researcher Shusaku Uchida. Continue reading

Save the Date! ‘New Jersey Rare Disease Day 2017’ Set for February 27 in Trenton

Rare Disease DayTrenton, NJ, January 29, 2017 — New Jersey’s rare disease community will gather to celebrate Rare Disease Day 2017 on Monday, February 27 from 9:00 a.m. to 12:00 p.m. at the New Jersey Business and Industry Association (NJBIA) at 10 West Lafayette Street in Trenton.

The half-day event will be sponsored by BioNJ, the HealthCare Institute of New Jersey (HINJ), New Jersey Rare Disease Alliance and NORD.

The morning will begin at 9:00 a.m. with coffee, pastries and networking, followed by speakers from the rare disease community, including patients, patient advocates, legislators, biomedical healthcare professionals and life sciences community leaders. Continue reading

Rutgers Cancer Institute of NJ Resident Receives $1.8M Grant to Explore Chronic Stress Role in Cancer Development

Wenwei Hu, Ph.D.

Wenwei Hu, Ph.D.

New Brunswick, NJ, January 28, 2017 — A five-year, $1.8 million grant (R01CA203965) from the National Cancer Institute awarded to Rutgers Cancer Institute of New Jersey resident research member Wenwei Hu, Ph.D., will support research to further elucidate the mechanisms behind the most frequently mutated gene in human tumors – p53.

The aim is to explore how chronic stress impacts cancer development, especially when cancers containing a mutation in p53, and identify molecular targets that would disrupt the effect of chronic stress on cancer development.

The p53 protein plays a central role in preventing cancer development, as loss of its tumor suppressor function has been shown to contribute greatly to cancer development. Continue reading

New Director of Rutgers Cancer Institute of NJ Outlines 2017 Goals

Dr. Steven K. Libutti

Dr. Steven K. Libutti

New Brunswick, NJ, January 27, 2017 — Minna Kim reports that the Rutgers Cancer Institute of New Jersey (RCINJ) began the new year under the leadership of new Director Steven Libutti, who assumed the position on January 10.

One immediate responsibility that the new director will hold is ensuring that RCINJ is renewed as one of the 47 designated Comprehensive Care Centers of the National Cancer Institute (NCI).  This will be determined one year from now, Libutti said.

“Competitive grants are awarded to cancer centers that exceed certain criteria, that and expectations that the National Cancer Institute sets,” he said.  “Every five to seven years, we have to re-compete for the designation and grant.” Continue reading

Gov. Christie Nominates Kimberley Harrington to Serve as State’s Education Commissioner

Kimberley Harrington

Kimberley Harrington

Trenton, NJ, January 26, 2017 — Adam Clark reports in The Star-Ledger that Gov. Chris Christie on January 23 nominated acting Education Commissioner Kimberley Harrington to formally serve as the state’s school chief during his final year in office, according to

Harrington, who has been acting commissioner since September, is a former teacher and administrator.  She began working for the state Department of Education in 2012 as director of academic standards.

Former Education Commissioner David Hespe, who became acting commissioner in February 2014 and was confirmed in December 2014, resigned to work for the Schwartz Simon Edelstein & Celso law firm in Whippany. Continue reading

Gov. Christie, Lawmakers Move on Aggressive Bill to Tackle NJ Addiction Crisis

Drug Abuse help 2Trenton, NJ, January 25, 2017 — Susan K. Livio reports in The Star-Ledger that far-reaching legislation Gov. Chris Christie outlined in his State of the State address that would prevent opioid addiction and reduce economic barriers to inpatient drug treatment is expected to get a hearing as early as next week, one of the prime sponsors of the bill confirmed Monday.

Gov. Christie, in his Jan. 11 speech, said he wanted the Democrat-controlled legislature to pass the insurance bill within 30 days, while ordering Attorney General Christopher Porrino to quickly adopt rules limits opioid prescriptions.

Though still in the draft stage, the aggressive bill requires insurance companies to admit addicts without delay into an inpatient treatment program regardless of their ability to pay, for a maximum of six months, according to Senate Health Committee Chairman Joseph Vitale (D-Middlesex), one of bill’s prime sponsors. Continue reading

Rutgers’ Ronke Olabisi Aims to Develop Biomaterials that Can Speed Healing in Space and on Earth

Ronke Olabisi

Ronke Olabisi

New Brunswick, NJ, January 25, 2017Ronke Olabisi once dreamed of becoming an astronaut.  Now she’s conducting research that could help space travelers and Earth-dwellers heal faster and stay healthy.

“If healing people faster on Earth is going to be helpful, then it’s really going to be helpful in space,” said Olabisi, an assistant professor in Rutgers’ Department of Biomedical Engineering. “Spaceflight affects every single system.”

Bones, muscle and other tissues gradually break down in space, posing major problems for anyone wanting to go to Mars and beyond, said Olabisi, who works in the School of Engineering. Continue reading

Event: Montclair State University to Host ‘Trump’s First 100 Days: What It Might Mean for Innovation and Entrepreneurship’ on January 30

Donald Trump 1Montclair, NJ, January 25, 2017 — Donald J. Trump was an unconventional candidate, and many expect him to be an unconventional president. What will this mean in the areas of innovation and entrepreneurship?  What can we expect from a Trump White House? How will the Democrats interact with a Trump administration?

Join Montclair State University’s Feliciano Center for Entrepreneurship and Department of Political Science on Monday, January 30 from 6:00 to 8:30 p.m. as a panel of experts provides insight on these questions and on how a Trump administration could impact entrepreneurs, startup founders, innovators and inventors.   Continue reading

U.S. Biopharmaceutical Companies Launch GoBOLDLY, A Groundbreaking, Multi-Year Initiative Heralding New Era of Medicine

PhRMA Innovation logoWashington, DC, January 24, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) yesterday launched a national, multi-year advertising and public affairs initiative on behalf of America’s biopharmaceutical companies.

The campaign, GOBOLDLY, will showcase the industry’s unsung heroes driving cutting-edge advances in science and highlight the tremendous opportunity that exists to tackle our most complex and devastating health conditions.

“Thanks to the tireless work of biopharmaceutical researchers and scientists, we have entered a new era of medicine that is transforming the way we prevent and treat disease.  This campaign spotlights their perseverance and unwavering commitment to American patients for whom we all work,” said Stephen J. Ubl, president and chief executive officer of PhRMA. Continue reading